Mr. Matt Coffey reports

ONCOLYTICS BIOTECH ANNOUNCES POSTER PRESENTATION DEMONSTRATING THE ABILITY OF REOLYSIN TO PROMOTE AND PREDICT RESPONSE TO CHECKPOINT INHIBITORS AT ASCO 2018 ANNUAL MEETING

Oncolytics Biotech Inc. will make a key poster presentation at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. The meeting takes place from June 1 to June 5, 2018, at McCormick Place, Chicago, Ill.

"These results demonstrate that pelareorep promotes the expression of gene signatures predictive of a response to immunotherapy in breast cancer and hepatocellular carcinoma," said Matt Coffey, president and chief executive officer of Oncolytics Biotech. "The tumour inflammation promoting effects in breast cancer models provide a compelling explanation for the significant overall survival benefit in hormone receptor positive metastatic breast cancer patients in our phase 2, IND 213, study and we believe this will continue to drive interest in our breast cancer program."

Highlights of the poster include:

• Pelareorep promotes expression of gene signatures that are predictive of response to checkpoint inhibitors in select cell lines:
  • HCC -- hepatocellular carcinoma;
  • HR+ BC -- hormone receptor positive breast cancer;
• Pronounced tumour inflammatory effects of pelareorep in HR+ BC cells may explain the prominent increase in overall survival in a previous phase 2 randomized clinical study in HR+ mBC patients treated with pelareorep and may render this large breast cancer population susceptible to conventional immunotherapy regimes;
• Results warrant further investigation of pelareorep in combination with checkpoint inhibitors.

Presenter and lead author:  Grey A. Wilkinson, PhD, Oncolytics scientist, translational medicine

Presentation title:  Pelareorep to promote the expression of an IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy

Session title:  developmental therapeutics -- immunotherapy

Location:  McCormick Place, Hall A

Abstract No.:  3089

Poster board No.:  303

Date/time:  June 4, 2018; 8 a.m. to 11:30 a.m.

The complete poster can be found on-line on the company's website.

About Reolysin/pelareorep

Reolysin, also known as pelareorep, is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumours and hematological malignancies. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype through innate and adaptive immune responses to treat a variety of cancers.

We seek Safe Harbor.